about
Morbid obesity resulting from inactivation of the ciliary protein CEP19 in humans and miceCoordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1Metformin-associated lactic acidosis: Current perspectives on causes and riskTreatment of prediabetesDoes reduced IGF-1R signaling in Igf1r+/- mice alter aging?Impaired fasting glucose and impaired glucose tolerance: implications for careAssociation of neuropeptide Y receptor Y5 polymorphisms with dyslipidemia in Mexican AmericansCoordinated defects in hepatic long chain fatty acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primatesThe genetic architecture of type 2 diabetesOmics-squared: human genomic, transcriptomic and phenotypic data for genetic analysis workshop 19.Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humansSuccessful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.Plasma glucose concentration and prediction of future risk of type 2 diabetes.Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type Adult Mice.The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose toleranceEffect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response studyEffects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.Pathogenesis of insulin resistance in skeletal muscle.The ontogeny of insulin signaling in the preterm baboon model.Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individualsStrong association between insulin-mediated glucose uptake and the 2-hour, not the fasting plasma glucose concentration, in the normal glucose tolerance range.Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose.Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWRole of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.NF-κB activity in muscle from obese and type 2 diabetic subjects under basal and exercise-stimulated conditions.Adjusting glucose-stimulated insulin secretion for adipose insulin resistance: an index of β-cell function in obese adults.Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneChronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.Insulin reduces plasma arginase activity in type 2 diabetic patients.Hypoadiponectinemia is closely associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjectsPeripheral insulin resistance and impaired insulin signaling contribute to abnormal glucose metabolism in preterm baboons.Reduction in reactive oxygen species production by mitochondria from elderly subjects with normal and impaired glucose toleranceGenome-wide linkage screen for systolic blood pressure in the Veterans Administration Genetic Epidemiology Study (VAGES) of Mexican-Americans and confirmation of a major susceptibility locus on chromosome 6q14.1.APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor.
P50
Q24309123-B0C04416-F42A-4729-9C89-949C69913AE9Q24679555-9CDEF9DD-0EB4-4CC7-8F94-27348660257BQ26771648-B626ABB9-CB51-4F2C-95C1-F06CBF073DDEQ26783350-3D1A582A-87B1-4812-A7AC-44B45A275868Q27314852-FB048F1C-A233-42E4-8C41-C16170FBCA56Q28290479-56471F05-EE94-48F5-985A-9902EF6F0341Q28297497-1E88B41D-AE2B-48DB-9821-DE79A58C31DAQ28478084-0A7B417E-86A8-4429-9A48-D3F6842BB73EQ29583824-DFD29B63-BA45-42E4-80F5-EFA42B166C8FQ31149227-C36DBBD7-07F0-4C3C-B145-2647B92F9D90Q33354192-F249D7D0-B752-4CF8-B8D7-DC5BBCD107E5Q33356608-5ABA6C43-604A-4D68-B36F-DD8592A6B751Q33578588-DB89C90C-15E2-4F9B-B0EB-1979AB494C80Q33610774-19E86D04-075D-43BF-B946-C28A2807E8F5Q33646501-E725270F-4ABC-46CB-B388-6C8DD84BE9F4Q33705046-EA8E253A-69BC-4F66-A35A-3EF9EC40F889Q33747784-14085190-2507-4D7D-8D7C-0E35CD76FFC0Q33786881-6B0D7089-8A6F-4724-868A-F3F7279F443AQ33804747-8C0856B3-2B24-415B-8084-462AB25C6C49Q33812448-AFAC7CDA-3D7F-412A-B470-497B6EB5C13AQ33848265-57EFC095-97DF-44AD-842B-0F50F9540E4FQ33959764-FA375F34-3CD9-4BA2-ABEE-AFA026270620Q34131002-4F6163D3-D063-470E-97A5-F0B71CEB0B9CQ34139048-13E5B511-06C2-418D-8667-81C7653F808FQ34204855-D807B9D8-EF63-4DE7-926C-812C217928CFQ34264630-30E78354-D037-4C0C-BCD2-15AD50BA0A82Q34294997-C880AD95-21C7-4950-A6C9-E9120542583EQ34305228-265A4F9F-01A4-44B3-BA0B-0AC2096E0982Q34392359-9A5E609F-8B8F-4A98-9420-41F5F74568AFQ34518606-36A7B4F7-A399-4EB4-8C8B-6A9953C3AA92Q34585893-3FD24FED-42D9-452A-BB4A-E403B6F0E881Q34608300-6FC16CB0-5806-4081-864B-CDFBAF74ADAFQ34780873-ADCEC0E0-A232-488B-9898-56A00FF8AFE7Q34876148-F27211E9-66B8-468A-9379-CE51DCD82895Q35005301-1AAF54D3-A116-4E50-979C-45D2C979C262Q35075030-453A023B-9B86-4F68-A476-F15BE910E4CBQ35088795-3A4EE421-BED5-49B5-B9B9-9A251D120C23Q35123509-DDAE158C-CE4D-46E2-98CA-C012F8E36618Q35153728-D4D0D203-987E-4947-B5A8-54EA7043C143Q35234727-27085F62-562D-4022-9823-E5034855D9A2
P50
description
researcher ORCID ID = 0000-0002-8581-6273
@en
wetenschapper
@nl
name
Ralph A DeFronzo
@en
Ralph A DeFronzo
@nl
Ralph A. DeFronzo
@de
Ralph A. DeFronzo
@es
type
label
Ralph A DeFronzo
@en
Ralph A DeFronzo
@nl
Ralph A. DeFronzo
@de
Ralph A. DeFronzo
@es
prefLabel
Ralph A DeFronzo
@en
Ralph A DeFronzo
@nl
Ralph A. DeFronzo
@de
Ralph A. DeFronzo
@es
P214
P227
P166
P21
P214
P227
P31
P496
0000-0002-8581-6273
P7859
viaf-237526486